MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
2.050
+0.140
+7.33%
After Hours: 2.050 0 0.00% 16:06 12/13 EST
OPEN
1.990
PREV CLOSE
1.910
HIGH
2.175
LOW
1.930
VOLUME
7.65M
TURNOVER
--
52 WEEK HIGH
3.179
52 WEEK LOW
0.3040
MARKET CAP
427.73M
P/E (TTM)
-2.7520
1D
5D
1M
3M
1Y
5Y
1D
TD Cowen Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)
TipRanks · 11h ago
SANGAMO THERAPEUTICS INC <SGMO.O>: TRUIST SECURITIES RAISES TO BUY FROM HOLD
Reuters · 11h ago
Sangamo Biosciences: Strategic Growth and Advancing Pipeline Drive Buy Rating
TipRanks · 12h ago
Sangamo upgraded to Buy from Hold at Truist
TipRanks · 12h ago
The Analyst Landscape: 6 Takes On Sangamo Therapeutics
Benzinga · 3d ago
Sangamo Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Benzinga · 3d ago
Promising Trial Results and Strategic Partnerships Drive Buy Rating for Sangamo Biosciences
TipRanks · 3d ago
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.